Overview

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
0
Participant gender:
All
Summary
This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic. Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day changes in insulin secretion and insulin sensitivity.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yaounde Central Hospital
Collaborators:
University of Buea
University of Yaounde 1
Treatments:
Insulin
Insulin, Globin Zinc
Liraglutide
Vildagliptin
Criteria
Inclusion Criteria:

- Type 2 diabetes mellitus known for at least one year

- Uncontrolled glycaemic profile with HbA1c ≥ 7% on oral antidiabetic mono or bi-therapy

- Naïve of incretinomimetic treatment

- Informed consent

Exclusion Criteria:

- Change in antidiabetic treatment less than 3 months prior to inclusion

- Pancreatitis

- Alanine amino transferase > 3 times the normal values

- Pregnant or breastfeeding women

- Estimated glomerular filtration rate < 60ml/min

- Infection less than 10 days prior to inclusion or during the study

- Acute complication of diabetes

- Total haemoglobin < 11g/dL in women or < 13g/dL in men

- Withdrawal of consent